The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
10 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,359,614 in first-year total cost, median $264,121.
Most frequent study sections
- Career Development Study Section (J)[NCI-J]10
Most frequent institutions
- SLOAN-KETTERING INST CAN RESEARCH3
- MASSACHUSETTS GENERAL HOSPITAL2
- DANA-FARBER CANCER INST1
- ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI1
- UNIVERSITY OF CALIFORNIA AT DAVIS1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2024 | Barriers and Facilitators for Delivery of Guideline-Concordant Care for Adolescents and Young Adults with Ewing Sarcoma and Osteosarcoma1K08CA288912-01 | ALVAREZ, ELYSIA | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $281,565 | NCI |
| 2024 | Initiating Colorectal Cancer Screening in Unscreened Individuals 45 to 541K08CA285952-01A1 | ANYANE-YEBOA, ADJOA | MASSACHUSETTS GENERAL HOSPITAL, MA | $197,640 | NCI |
| 2024 | Optimization of anal cancer screening for people with HIV using genomic methods1K08CA285939-01 | SILVERA, RICHARD | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $187,148 | NCI |
| 2024 | Targeted Radionuclide Therapy to Enhance the Efficacy of CAR T Cells Against Neuroblastoma1K08CA285941-01A1 | SODJI, QUAOVI H | UNIVERSITY OF WISCONSIN-MADISON, WI | $159,636 | NCI |
| 2023 | Targeting regenerative reprogramming in colorectal cancer1K08CA279499-01 | ALONSO MARTINEZ, SALVADOR | SLOAN-KETTERING INST CAN RESEARCH, NY | $292,597 | NCI |
| 2023 | Health Opportunities & Promoters of Equitable Screening for Lung Cancer (Hopes for Lung Cancer)1K08CA270430-01A1 | FLORES, EFREN | MASSACHUSETTS GENERAL HOSPITAL, MA | $280,777 | NCI |
| 2023 | Microbial Dysbiosis in Pancreatic Cancer Initiation and Progression1K08CA282374-01 | DALEY, DONNELE | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $280,670 | NCI |
| 2023 | Investigating the Role of KEAP1 Germline and Somatic Mutations in Renal Cell Carcinoma1K08CA272960-01A1 | CARLO, MARIA | SLOAN-KETTERING INST CAN RESEARCH, NY | $258,998 | NCI |
| 2022 | Novel targeted therapies for chronic myelomonocytic leukemia1K08CA258803-01A1 | BELIZAIRE, ROGER VINCENT | DANA-FARBER CANCER INST, MA | $269,244 | NCI |
| 2022 | Role of Fc Receptors in the Therapeutic Activity of Antibodies Targeting the CD47-SIRP-alpha axis1K08CA266740-01A1 | OSORIO, JUAN C | SLOAN-KETTERING INST CAN RESEARCH, NY | $151,339 | NCI |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.